BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10695992)

  • 1. Absence of p51 mutation in human hepatocellular carcinoma.
    Hamada K; Koyama T; Shimizu K; Ikawa S; Kawate S; Yokota J; Ohwada S; Morishita Y
    Cancer Lett; 2000 Feb; 148(2):161-4. PubMed ID: 10695992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of p51 alteration in human ovarian cancer.
    Shinozaki H; Okamoto A; Shimizu K; Saito M; Yokota J; Ochiai K
    Int J Oncol; 2001 Mar; 18(3):549-52. PubMed ID: 11179485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma.
    Takahashi H; Fukutome K; Watanabe M; Furusato M; Shiraishi T; Ito H; Suzuki H; Ikawa S; Hano H
    Prostate; 2001 May; 47(2):85-90. PubMed ID: 11340630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation and expression of the p51 gene in human lung cancer.
    Tani M; Shimizu K; Kawahara C; Kohno T; Ishimoto O; Ikawa S; Yokota J
    Neoplasia; 1999 Apr; 1(1):71-9. PubMed ID: 10935472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia.
    Yamaguchi H; Inokuchi K; Sakuma Y; Dan K
    Leukemia; 2001 Nov; 15(11):1729-34. PubMed ID: 11681414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation and transcription analyses of the p63 gene in cervical carcinoma.
    Nishi H; Isaka K; Sagawa Y; Usuda S; Fujito A; Ito H; Senoo M; Kato H; Takayama M
    Int J Oncol; 1999 Dec; 15(6):1149-53. PubMed ID: 10568821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
    Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
    Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of p33(ING1b) and p53 gene expression in hepatocellular carcinoma].
    Zhu Z; Zhu M; Ni C
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1332-6. PubMed ID: 12509938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
    Pogribny IP; James SJ
    Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
    Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
    Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression but lack of mutation and methylation of p73 in hepatocellular carcinoma.
    Pan H; Liao SJ; Lai WY; Lu HC; Hsiao KM
    Acta Oncol; 2002; 41(6):550-5. PubMed ID: 12546528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma.
    Kawate S; Takenoshita S; Ohwada S; Mogi A; Fukusato T; Makita F; Kuwano H; Morishita Y
    Int J Oncol; 1999 Jan; 14(1):127-31. PubMed ID: 9863018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mutation analysis of the tumor suppressor gene PTEN/MMAC1/TEP1 in human hepatocellular carcinoma].
    Zhang LN; Zha XL; Yu Q; He JY
    Shi Yan Sheng Wu Xue Bao; 2000 Sep; 33(3):223-7. PubMed ID: 12549040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
    Katiyar S; Dash BC; Thakur V; Guptan RC; Sarin SK; Das BC
    Cancer; 2000 Apr; 88(7):1565-73. PubMed ID: 10738214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning and functional analysis of human p51, which structurally and functionally resembles p53.
    Osada M; Ohba M; Kawahara C; Ishioka C; Kanamaru R; Katoh I; Ikawa Y; Nimura Y; Nakagawara A; Obinata M; Ikawa S
    Nat Med; 1998 Jul; 4(7):839-43. PubMed ID: 9662378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.
    Kang MS; Lee HJ; Lee JH; Ku JL; Lee KP; Kelley MJ; Won YJ; Kim ST; Park JG
    Int J Cancer; 1996 Sep; 67(6):898-902. PubMed ID: 8824565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma.
    Park SW; Durkin ME; Thorgeirsson SS; Popescu NC
    Int J Oncol; 2003 Jul; 23(1):133-7. PubMed ID: 12792785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53CP is p51/p63, the third member of the p53 gene family: partial purification and characterization.
    Tan M; Bian J; Guan K; Sun Y
    Carcinogenesis; 2001 Feb; 22(2):295-300. PubMed ID: 11181451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of the Smad6 and Smad7 genes in hepatocellular carcinoma.
    Kawate S; Ohwada S; Hamada K; Koyama T; Takenoshita S; Morishita Y; Hagiwara K
    Int J Mol Med; 2001 Jul; 8(1):49-52. PubMed ID: 11408948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non HCC prevalent area in China.
    Liu H; Wang Y; Zhou Q; Gui SY; Li X
    World J Gastroenterol; 2002 Jun; 8(3):480-2. PubMed ID: 12046074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.